CV — Q2 2026 Financial Report Analysis

CapsoVision makes CapsoCam Plus, a pill-sized camera that a patient swallows so a doctor can review a video of the small intestine without inserting a scope. In the second quarter of 2026 (April to June) it sold 13% more capsules than a year earlier, which lifted revenue 10% to $3.6 million even though the average price per capsule fell about 3%. Spending grew far faster than sales: operating expenses rose 46% to $9.5 million, mostly for clinical trials of its next product (a colon capsule) and an image-sensor development project with Canon, so the net loss widened 62% to $7.5 million. The company had $9.1 million of cash at June 30 and says in the filing that this is not enough to fund the next 12 months; it has since raised about $18 million from existing shareholders.

At a glance

• Revenue +10% to $3.6M, all from volume: capsules sold rose 13% while the average selling price slipped about 3% on what management calls competitive pricing pressure.
• Gross margin 51%, down from 55%. Gross margin is the share of each sales dollar left after the cost of making and delivering the product; lower prices and new U.S. customs and tariff costs on imported components took about 3 points off it.
• $14.5M of cash used in operations in the first half vs $9.1M of cash left at June 30. The filing carries a "going concern" warning (management's formal statement that it doubts it can keep operating for a year without new money), which the September share sale partly addresses.

The numbers

Operating margin is operating profit (here, loss) as a share of revenue: at -208%, the company spent about $3.08 running the business for every $1 of sales.

Where the growth came from, and where it didn't

Revenue grew 7% in the U.S. and 20% internationally, where CapsoVision sells through distributors; international now makes up a quarter of sales. The quarter was much better than the first: first-half revenue was up only 6% ($6.4 million vs $6.1 million), which means the January–March quarter was essentially flat at about $2.8 million in both years, and U.S. revenue grew just 1% over the half. One strong quarter is not yet a trend.

Volume is doing all the work. The 10-Q attributes the 3% price decline to "competitive pricing pressure" — CapsoVision competes with much larger capsule makers in a market where hospitals and group purchasing organizations negotiate hard. Combined with tariffs, that is why gross profit grew only 3% on 10% more revenue: cost of revenue rose 18%.

Where the money went

• R&D +$1.9M (+57%) to $5.3M. The filing breaks this down: $1.3 million more for clinical trials (chiefly the colon capsule's pivotal study — the large trial the FDA reviews before clearing a device — and a study of an upper-GI capsule for pancreatic cancer detection), $0.4 million more for engineering work on a new CMOS image sensor (the chip that captures the images) being developed with Canon, and small increases in headcount and stock-based pay. Canon development costs booked as R&D were $470,000 this quarter.
• G&A +$1.0M (+80%) to $2.2M. About $0.2 million is the cost of being public (insurance, board pay), $0.3 million is stock-based compensation, and $0.1 million is software. The rest is a flattering prior year: Q2 2025 expenses were reduced by a $0.2 million COVID-19 relief payment and about $0.2 million of foreign-exchange gains that did not recur.
• Selling and marketing +5% to $1.9M, driven by new stock-option grants rather than more salespeople this quarter.

What the headline numbers hide

• Cash burn, not the income statement, is the real constraint. Cash used in operations was $14.5 million in the first half, essentially equal to the $14.5 million net loss — there is no gap between accounting loss and cash loss to take comfort from. The company ended June with $9.1 million, roughly one quarter's burn at the current rate, and only stayed there because a March private placement brought in $13.4 million net.
• Inventory is building much faster than sales. Inventory rose 57% in six months, from $3.0 million to $4.7 million, consuming $1.7 million of cash, while first-half revenue grew 6%. The filing does not explain the build; it could be stocking ahead of tariff changes or new launches, but it ties up scarce cash either way. Receivables, by contrast, fell slightly ($2.5 million to $2.3 million), so customers are paying normally.
• The EPS comparison is meaningless. Loss per share "improved" from -$2.02 to -$0.15 only because the share count went from 2.3 million weighted shares to 49.9 million: before the July 2025 IPO, most investors held preferred stock that converted into common shares at the listing. The loss itself grew 62%.
• No adjusted figures, no guidance. CapsoVision reports only GAAP numbers (no "adjusted" loss that strips out costs) and gives no revenue or earnings forecast. Stock-based compensation, a non-cash cost, was $0.9 million in the first half vs $0.3 million a year earlier.
• Internal controls are still flagged. Management again concluded its disclosure controls were not effective, citing two unremediated material weaknesses (IT access controls and too few finance staff to separate who records and who approves journal entries) first identified at the end of 2024.

Takeaway: The capsule business is growing on volume but not on price, and every extra dollar of revenue is being outrun by trial and development spending. CapsoVision is a funding story for now: with about one quarter of cash on hand at June 30, its value depends on raising money on acceptable terms until the colon capsule — not the small-bowel product — can change the size of the business.

Since the quarter ended

• Funding: on August 13 the company set up an "at-the-market" program to sell up to $100 million of new shares gradually through Cantor Fitzgerald, and on September 17 it agreed to sell 3,163,444 shares at $5.69 (about a 5% discount to the prior close) to existing shareholders, including two holders of more than 5% of the stock, for about $18 million gross ($17.8 million net estimated). That roughly covers two to three quarters at the first-half burn rate, and it dilutes existing holders by about 6%.
• Product: AI Highlights, an AI-assisted reading feature that helps physicians review capsule videos, launched in Europe during the quarter and received FDA clearance on September 25, 2026, in line with management's "end of the third quarter" target. U.S. launch was expected shortly after clearance.

What to watch

The third-quarter report (expected around mid-November 2026) is the first with AI Highlights cleared in the U.S., so the question is whether U.S. growth moves beyond the 1% of the first half or the 7% of Q2, and whether price declines stop. On spending, management has said the colon capsule is on track for a 510(k) submission (the FDA filing for clearance of a device similar to ones already on the market) in the fourth quarter of 2026, with commercial launch targeted within one quarter after clearance; trial costs should peak around that submission. Our read: R&D is unlikely to fall before the colon capsule is filed, so losses near $7–8 million a quarter look like the base case, and the share count is likely to keep rising through the at-the-market program. A clearance for the colon capsule would matter far more to the company's trajectory than any single quarter of small-bowel sales.